Results 31 to 40 of about 2,675,396 (301)

Could Mucosal TNF Transcript as a Biomarker Candidate Help Optimize Anti-TNF Biological Therapy in Patients With Ulcerative Colitis?

open access: yesFrontiers in Immunology, 2022
Anti-tumor necrosis factor (TNF) biological therapy has generally been accepted as a standard therapeutic option in inflammatory bowel disease (IBD) patient who are refractory to steroids or immunomodulators.
Guanglin Cui   +4 more
doaj   +1 more source

Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNF alpha therapy [PDF]

open access: yes, 2004
Regulatory T cells have been clearly implicated in the control of disease in murine models of autoimmunity. The paucity of data regarding the role of these lymphocytes in human autoimmune disease has prompted us to examine their function in patients with
Jamie G. Evans   +13 more
core   +1 more source

Combination of subtherapeutic anti-TNF dose with dasatinib restores clinical and molecular arthritogenic profiles better than standard anti-TNF treatment. [PDF]

open access: yes, 2021
BACKGROUND New medications for Rheumatoid Arthritis (RA) have emerged in the last decades, including Disease Modifying Antirheumatic Drugs (DMARDs) and biologics.
Kollias, G.   +22 more
core   +2 more sources

The Interplay between Mucosal Microbiota Composition and Host Gene-Expression is Linked with Infliximab Response in Inflammatory Bowel Diseases

open access: yesMicroorganisms, 2020
Even though anti-TNF therapy significantly improves the rates of remission in inflammatory bowel disease (IBD) patients, there is a noticeable subgroup of patients who do not respond to treatment.
Nikolas Dovrolis   +7 more
doaj   +1 more source

The differential contribution of tumour necrosis factor to thermal and mechanical hyperalgesia during chronic inflammation [PDF]

open access: yes, 2005
Therapies directed against tumour necrosis factor (TNF) are effective for the treatment of rheumatoid arthritis and reduce pain scores in this condition.
Inglis, JJ   +11 more
core   +1 more source

Calcineurin inhibitors in steroid and anti‐TNF‐alpha refractory immune checkpoint inhibitor colitis

open access: yesJGH Open, 2021
Background and Aim Immune checkpoint inhibitor (ICI) colitis is an increasingly common problem encountered as the use of checkpoint inhibitors (CPIs) grows in the management of cancers.
Eva Zhang   +3 more
doaj   +1 more source

Anti-TNF-α plasma level and anti-drug antibodies.

open access: yes, 2016
(A) Adalimumab concentration in plasma from patients with psoriasis who respond (R) or do not respond (NR) to therapy ...
Federica Ferrari (3391226)   +14 more
core   +1 more source

Synergistic and antagonistic effects of TNF-[alpha] and IGF-I in heart failure : "in vitro" and "in vivo" study of cardiac and skeletal muscle [PDF]

open access: yes, 2006
Cardiovascular diseases are a major cause of morbidity and mortality in industrialized countries. All forms of myocardial injury first lead to compensatory hypertrophy, which eventually progresses to heart failure.
Murigande, Claire
core   +1 more source

Analysis of Publications on Psoriasis and Tuberculosis

open access: yesGenel Tıp Dergisi
Background: Psoriasis is a relatively common inflammatory disease globally with systemic implications and the treatment of psoriasis has advanced rapidly in recent years. However, current treatments, especially anti tumor necrosis factor (TNF) treatments,
Sevil Alkan   +2 more
doaj   +1 more source

Anti-tumor necrosis factor-α is potentially better than tumor necrosis factor-α as the biomarker for sarcopenia: Results from the I-Lan longitudinal aging study

open access: yesExperimental Gerontology, 2023
Tumor necrosis factor (TNF)-α is a proinflammatory cytokine involved in the pathogenesis of sarcopenia, but its short half-life and inconsistent reproducibility limit the potential of TNF-α to be an ideal sarcopenia biomarker.
Wei-Ju Lin   +7 more
doaj   +1 more source

Home - About - Disclaimer - Privacy